Gender Differences in Psoriasis

  • Sivan Sheffer Levi
  • Yuval Ramot
Chapter

Abstract

The effects of gender on psoriasis are not well established and published data are sparse and inconclusive. Review of the literature reveals interesting gender-specific differences in various aspects of the disease, including epidemiology, pathogenesis, clinical characteristics, comorbidities, quality of life and treatment. These differences may be influenced by multiple factors, including skin anatomy, physiology, genetics and hormones, but also social, cultural and environmental factors. Such differences may have implications regarding gender-related management and prognosis, but further research is needed to better define these differences.

Keywords

Psoriasis Sex hormones Alcohol Smoking Stress Psoriatic arthritis Comorbidities Quality of life Biologic agents 

References

  1. 1.
    Stern RS, Nijsten T, Feldman SR, Margolis DJ, Rolstad T. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc. 2004;9(2):136–9.Google Scholar
  2. 2.
    Gelfand JM, Weinstein R, Porter SB, Neimann AL, Berlin JA, Margolis DJ. Prevalence and treatment of psoriasis in the United Kingdom: a population-based study. Arch Dermatol. 2005;141(12):1537–41.Google Scholar
  3. 3.
    Kurd SK, Gelfand JM. The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: results from NHANES 2003-2004. J Am Acad Dermatol. 2009;60(2):218–24.Google Scholar
  4. 4.
    Krueger J, Bowcock A. Psoriasis pathophysiology: current concepts of pathogenesis. Ann Rheum Dis. 2005;64(Suppl 2):ii30–6.PubMedPubMedCentralGoogle Scholar
  5. 5.
    Langley RG, Krueger GG, Griffiths CE. Psoriasis: epidemiology, clinical features, and quality of life. Ann Rheum Dis. 2005;64(Suppl 2):ii18–23; discussion ii4-5.PubMedPubMedCentralGoogle Scholar
  6. 6.
    Sander HM, Morris LF, Phillips CM, Harrison PE, Menter A. The annual cost of psoriasis. J Am Acad Dermatol. 1993;28(3):422–5.Google Scholar
  7. 7.
    Javitz HS, Ward MM, Farber E, Nail L, Vallow SG. The direct cost of care for psoriasis and psoriatic arthritis in the United States. J Am Acad Dermatol. 2002;46(6):850–60.Google Scholar
  8. 8.
    Colombo D, Cassano N, Bellia G, Vena GA. Gender medicine and psoriasis. World J Dermatol. 2014;3(3):36–44.Google Scholar
  9. 9.
    Christophers E. Psoriasis: epidemiology and clinical spectrum. Clin Exp Dermatol. 2001;26(4):314–20.Google Scholar
  10. 10.
    Gudjonsson JE, Elder JT. Psoriasis: epidemiology. Clin Dermatol. 2007;25(6):535–46.Google Scholar
  11. 11.
    Farber EM, Nall L. Epidemiology in psoriasis research. Hawaii Med J. 1982;41(11):430–42.Google Scholar
  12. 12.
    Tollefson MM, Crowson CS, McEvoy MT, Kremers HM. Incidence of psoriasis in children: a population-based study. J Am Acad Dermatol. 2010;62(6):979–87.Google Scholar
  13. 13.
    Bell LM, Sedlack R, Beard CM, Perry HO, Michet CJ, Kurland LT. Incidence of psoriasis in Rochester, Minn, 1980-1983. Arch Dermatol. 1991;127(8):1184–7.Google Scholar
  14. 14.
    Icen M, Crowson CS, McEvoy MT, Dann FJ, Gabriel SE, Kremers HM. Trends in incidence of adult-onset psoriasis over three decades: a population-based study. J Am Acad Dermatol. 2009;60(3):394–401.PubMedPubMedCentralGoogle Scholar
  15. 15.
    Yip SY. The prevalence of psoriasis in the mongoloid race. J Am Acad Dermatol. 1984;10(6):965–8.Google Scholar
  16. 16.
    Takahashi H, Nakamura K, Kaneko F, Nakagawa H, Iizuka H. Analysis of psoriasis patients registered with the Japanese Society for Psoriasis Research from 2002-2008. J Dermatol. 2011;38(12):1125–9.Google Scholar
  17. 17.
    Zhang X, Wang H, Te-Shao H, Yang S, Chen S. The genetic epidemiology of psoriasis vulgaris in Chinese Han. Int J Dermatol. 2002;41(10):663–9.Google Scholar
  18. 18.
    Bedi TR. Psoriasis in North India. Geographical variations. Dermatologica. 1977;155(5):310–4.Google Scholar
  19. 19.
    Tsai TF, Wang TS, Hung ST, Tsai PI, Schenkel B, Zhang M, et al. Epidemiology and comorbidities of psoriasis patients in a national database in Taiwan. J Dermatol Sci. 2011;63(1):40–6.Google Scholar
  20. 20.
    Na SJ, Jo SJ, Youn JI. Clinical study on psoriasis patients for past 30 years (1982-2012) in Seoul National University Hospital Psoriasis Clinic. J Dermatol. 2013;40(9):731–5.Google Scholar
  21. 21.
    Kassi K, Djeha D, Gbery IP, Kouame K, Sangare A. Psoriasis in elderly patients in the Cote d’Ivoire: socio-demographic, clinical, and therapeutic aspects, and follow-up. Int J Dermatol. 2016;55(2):e83–6.Google Scholar
  22. 22.
    Könönen M, Torppa J, Lassus A. An epidemiological survey of psoriasis in the greater Helsinki area. Acta Derm Venereol Suppl. 1985;124:1–10.Google Scholar
  23. 23.
    Kundakci N, Tursen U, Babiker MO, Gurgey E. The evaluation of the sociodemographic and clinical features of Turkish psoriasis patients. Int J Dermatol. 2002;41(4):220–4.Google Scholar
  24. 24.
    Kaur I, Handa S, Kumar B. Natural history of psoriasis: a study from the Indian subcontinent. J Dermatol. 1997;24(4):230–4.Google Scholar
  25. 25.
    Olsen AO, Grjibovski A, Magnus P, Tambs K, Harris JR. Psoriasis in Norway as observed in a population-based Norwegian twin panel. Br J Dermatol. 2005;153(2):346–51.Google Scholar
  26. 26.
    Mallon E, Bunce M, Wojnarowska F, Welsh K. HLA-CW*0602 is a susceptibility factor in type I psoriasis, and evidence Ala-73 is increased in male type I psoriatics. J Invest Dermatol. 1997;109(2):183–6.Google Scholar
  27. 27.
    Kim TG, Lee HJ, Youn JI, Kim TY, Han H. The association of psoriasis with human leukocyte antigens in Korean population and the influence of age of onset and sex. J Invest Dermatol. 2000;114(2):309–13.Google Scholar
  28. 28.
    Hoede K. The problem of heredity of soriasis. Hautartz. 1957;8(10):433–8.Google Scholar
  29. 29.
    Lomholt G, Anna L. Psoriasis. Prevalence, spontaneous course, and genetics. A census study on the prevalence of skin diseases on the Faroe Islands (Translated by Anna la Cour) [A Thesis]. Copenhagen: G.E.C. Gad; 1963.Google Scholar
  30. 30.
    Hansen HE. Psoriasis in monozygotic twins: variations in expression in individuals with identical genetic constitution. Acta Derm Venereol. 1982;62:229–36.Google Scholar
  31. 31.
    Duffy D, Spelman L, Martin N. Psoriasis in Australian twins. J Am Acad Dermatol. 1993;29(3):428–34.Google Scholar
  32. 32.
    Farber E, Nall M. The natural history of psoriasis in 5,600 patients. Dermatology. 1974;148(1):1–18.Google Scholar
  33. 33.
    Sagoo GS, Cork MJ, Patel R, Tazi-Ahnini R. Genome-wide studies of psoriasis susceptibility loci: a review. J Dermatol Sci. 2004;35(3):171–9.Google Scholar
  34. 34.
    Tiilikainen A, Lassus A, Karvonen J, Vartiainen P, Julin M. Psoriasis and HLA-Cw6. Br J Dermatol. 1980;102(2):179–84.Google Scholar
  35. 35.
    Henseler T, Christophers E. Psoriasis of early and late onset: characterization of two types of psoriasis vulgaris. J Am Acad Dermatol. 1985;13(3):450–6.Google Scholar
  36. 36.
    Guðjónsson JE, Karason A, Antonsdottir AA, Rúnarsdottir EH, Gulcher JR, Stefansson K, et al. HLA-Cw6-positive and HLA-Cw6-negative patients with psoriasis vulgaris have distinct clinical features. J Invest Dermatol. 2002;118(2):362–5.Google Scholar
  37. 37.
    Nguyen CM, Liao W. Genomic imprinting in psoriasis and atopic dermatitis: a review. J Dermatol Sci. 2015;80(2):89–93.PubMedPubMedCentralGoogle Scholar
  38. 38.
    Gelfand JM, Gladman DD, Mease PJ, Smith N, Margolis DJ, Nijsten T, et al. Epidemiology of psoriatic arthritis in the population of the United States. J Am Acad Dermatol. 2005;53(4):573.Google Scholar
  39. 39.
    Buntin DM, Skinner RB Jr, Rosenberg EW. Onset of psoriasis at age 108. J Am Acad Dermatol. 1983;9(2):276–7.Google Scholar
  40. 40.
    Shbeeb M, Uramoto KM, Gibson LE, O’Fallon WM, Gabriel SE. The epidemiology of psoriatic arthritis in Olmsted County, Minnesota, USA, 1982-1991. J Rheumatol. 2000;27(5):1247–50.Google Scholar
  41. 41.
    Cassano N, Vestita M, Apruzzi D, Vena GA. Alcohol, psoriasis, liver disease, and anti-psoriasis drugs. Int J Dermatol. 2011;50(11):1323–31.Google Scholar
  42. 42.
    Naldi L, Peli L, Parazzini F. Association of early-stage psoriasis with smoking and male alcohol consumption: evidence from an Italian case-control study. Arch Dermatol. 1999;135(12):1479–84.Google Scholar
  43. 43.
    Gerdes S, Zahl V, Weichenthal M, Mrowietz U. Smoking and alcohol intake in severely affected patients with psoriasis in Germany. Dermatology. 2009;220(1):38–43.Google Scholar
  44. 44.
    Zou L, Lonne-Rahm S-B, Helander A, Stokkeland K, Franck J, Nordlind K. Alcohol intake measured by phosphatidylethanol in blood and the lifetime drinking history interview are correlated with the extent of psoriasis. Dermatology. 2015;230(4):375–80.Google Scholar
  45. 45.
    Gupta MA, Schork NJ, Gupta AK, Ellis CN. Alcohol intake and treatment responsiveness of psoriasis: a prospective study. J Am Acad Dermatol. 1993;28(5):730–2.Google Scholar
  46. 46.
    Higgins E. Alcohol, smoking and psoriasis. Clin Exp Dermatol. 2000;25(2):107–10.Google Scholar
  47. 47.
    Richer V, Roubille C, Fleming P, Starnino T, McCourt C, McFarlane A, et al. Psoriasis and smoking a systematic literature review and meta-analysis with qualitative analysis of effect of smoking on psoriasis severity. J Cutan Med Surg. 2016.  https://doi.org/10.1177/1203475415616073.
  48. 48.
    Li W, Han J, Choi HK, Qureshi AA. Smoking and risk of incident psoriasis among women and men in the United States: a combined analysis. Am J Epidemiol. 2012;175(5):402–13.PubMedPubMedCentralGoogle Scholar
  49. 49.
    Fortes C, Mastroeni S, Leffondré K, Sampogna F, Melchi F, Mazzotti E, et al. Relationship between smoking and the clinical severity of psoriasis. Arch Dermatol. 2005;141(12):1580–4.Google Scholar
  50. 50.
    Poikolainen K, Reunala T, Karvonen J, Lauharanta J, Kärkkäinen P. Alcohol intake: a risk factor for psoriasis in young and middle aged men? Br Med J. 1990;300(6727):780–3.Google Scholar
  51. 51.
    Poikolainen K, Reunala T, Karvonen J. Smoking, alcohol and life events related to psoriasis among women. Br J Dermatol. 1994;130(4):473–7.Google Scholar
  52. 52.
    Naldi L, Chatenoud L, Linder D, Fortina AB, Peserico A, Virgili AR, et al. Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case–control study. J Invest Dermatol. 2005;125(1):61–7.Google Scholar
  53. 53.
    Nakanishi N, Takatorige T, Suzuki K. Cigarette smoking and the risk of the metabolic syndrome in middle-aged Japanese male office workers. Ind Health. 2005;43(2):295–301.Google Scholar
  54. 54.
    Owczarczyk-Saczonek AB, Nowicki R. The association between smoking and the prevalence of metabolic syndrome and its components in patients with psoriasis aged 30 to 49 years. Postepy Dermatol Alergol. 2015;32:331–6.PubMedPubMedCentralGoogle Scholar
  55. 55.
    Naldi L. Epidemiology of psoriasis. Curr Drug Targets Inflamm Allergy. 2004;3(2):121–8.Google Scholar
  56. 56.
    Naldi L, Peli L, Parazzini F, Carrel CF, Psoriasis Study Group of the Italian Group for Epidemiological Research in Dermatology. Family history of psoriasis, stressful life events, and recent infectious disease are risk factors for a first episode of acute guttate psoriasis: results of a case-control study. J Am Acad Dermatol. 2001;44(3):433–8.Google Scholar
  57. 57.
    Seville R. Psoriasis and stress. Br J Dermatol. 1977;97(3):297–302.Google Scholar
  58. 58.
    Park BS, Youn JI. Factors influencing psoriasis: an analysis based upon the extent of involvement and clinical type. J Dermatol. 1998;25(2):97–102.Google Scholar
  59. 59.
    Picardi A, Mazzotti E, Gaetano P, Cattaruzza M, Baliva G, Melchi C, et al. Stress, social support, emotional regulation, and exacerbation of diffuse plaque psoriasis. Psychosomatics. 2005;46(6):556–64.Google Scholar
  60. 60.
    Gupta M, Gupta A, Grob J, Stern R, Mackie R, Weinstock W. Psychological factors and psoriasis. In: Epidemiology, causes and prevention of skin diseases. Oxford: Blackwell Science; 1997. p. 129–41.Google Scholar
  61. 61.
    Manolache L, Petrescu-Seceleanu D, Benea V. Life events involvement in psoriasis onset/recurrence. Int J Dermatol. 2010;49(6):636–41.Google Scholar
  62. 62.
    Campolmi E, Zanieri F, Santosuosso U, D’Erme A, Betti S, Lotti T, et al. The importance of stressful family events in psoriatic patients: a retrospective study. J Eur Acad Dermatol Venereol. 2012;26(10):1236–9.Google Scholar
  63. 63.
    Roman II, Constantin AM, Marina ME, Orasan RI. The role of hormones in the pathogenesis of psoriasis vulgaris. Clujul Med. 2016;89(1):11–8.PubMedPubMedCentralGoogle Scholar
  64. 64.
    Murase JE, Chan KK, Garite TJ, Cooper DM, Weinstein GD. Hormonal effect on psoriasis in pregnancy and post partum. Arch Dermatol. 2005;141(5):601–6.Google Scholar
  65. 65.
    Wheeler D, Grandinetti L. Psoriasis: evolving treatment for a complex disease. Cleve Clin J Med. 2012;79(6):413.Google Scholar
  66. 66.
    Ceovic R, Mance M, Bukvic Mokos Z, Svetec M, Kostovic K, Stulhofer Buzina D. Psoriasis: female skin changes in various hormonal stages throughout life—puberty, pregnancy, and menopause. Biomed Res Int. 2013;2013:571912.PubMedPubMedCentralGoogle Scholar
  67. 67.
    Cemil BC, Cengiz FP, Atas H, Ozturk G, Canpolat F. Sex hormones in male psoriasis patients and their correlation with the psoriasis area and severity index. J Dermatol. 2015;42(5):500–3.Google Scholar
  68. 68.
    Bouman A, Heineman MJ, Faas MM. Sex hormones and the immune response in humans. Hum Reprod Update. 2005;11(4):411–23.Google Scholar
  69. 69.
    Whitacre CC, Reingold SC, O’Looney PA, Blankenhorn E, Brinley F, Collier E, et al. A gender gap in autoimmunity. Science. 1999;283(5406):1277–8.Google Scholar
  70. 70.
    Farber EM, Nall ML. The natural history of psoriasis in 5,600 patients. Dermatologica. 1974;148(1):1–18.Google Scholar
  71. 71.
    Farley E, Masrour S, McKey J, Menter A. Palmoplantar psoriasis: a phenotypical and clinical review with introduction of a new quality-of-life assessment tool. J Am Acad Dermatol. 2009;60(6):1024–31.Google Scholar
  72. 72.
    Asumalahti K, Ameen M, Suomela S, Hagforsen E, Michaelsson G, Evans J, et al. Genetic analysis of PSORS1 distinguishes guttate psoriasis and palmoplantar pustulosis. J Invest Dermatol. 2003;120(4):627–32.Google Scholar
  73. 73.
    de Waal AC, van de Kerkhof PC. Pustulosis palmoplantaris is a disease distinct from psoriasis. J Dermatol Treat. 2011;22(2):102–5.Google Scholar
  74. 74.
    Eriksson MO, Hagforsen E, Lundin IP, Michaelsson G. Palmoplantar pustulosis: a clinical and immunohistological study. Br J Dermatol. 1998;138(3):390–8.Google Scholar
  75. 75.
    Hellgren L, Mobacken H. Pustulosis palmaris et plantaris. Prevalence, clinical observations and prognosis. Acta Derm Venereol. 1971;51(4):284–8.Google Scholar
  76. 76.
    Brunasso AM, Puntoni M, Aberer W, Delfino C, Fancelli L, Massone C. Clinical and epidemiological comparison of patients affected by palmoplantar plaque psoriasis and palmoplantar pustulosis: a case series study. Br J Dermatol. 2013;168(6):1243–51.Google Scholar
  77. 77.
    Adisen E, Tekin O, Gulekon A, Gurer MA. A retrospective analysis of treatment responses of palmoplantar psoriasis in 114 patients. J Eur Acad Dermatol Venereol. 2009;23(7):814–9.Google Scholar
  78. 78.
    Enfors W, Molin L. Pustulosis palmaris et plantaris. A follow-up study of a ten-year material. Acta Derm Venereol. 1971;51(4):289–94.Google Scholar
  79. 79.
    Gimenez-Garcia R, Sanchez-Ramon S, Cuellar-Olmedo LA. Palmoplantar pustulosis: a clinicoepidemiological study. The relationship between tobacco use and thyroid function. J Eur Acad Dermatol Venereol. 2003;17(3):276–9.Google Scholar
  80. 80.
    Miot HA, Miot LD, Lopes PS, Haddad GR, Marques SA. Association between palmoplantar pustulosis and cigarette smoking in Brazil: a case-control study. J Eur Acad Dermatol Venereol. 2009;23(10):1173–7.Google Scholar
  81. 81.
    Michaelsson G, Kristjansson G, Pihl Lundin I, Hagforsen E. Palmoplantar pustulosis and gluten sensitivity: a study of serum antibodies against gliadin and tissue transglutaminase, the duodenal mucosa and effects of gluten-free diet. Br J Dermatol. 2007;156(4):659–66.Google Scholar
  82. 82.
    Kumar B, Saraswat A, Kaur I. Palmoplantar lesions in psoriasis: a study of 3065 patients. Acta Derm Venereol. 2002;82(3):192–5.Google Scholar
  83. 83.
    Baker H, Ryan TJ. Generalized pustular psoriasis. A clinical and epidemiological study of 104 cases. Br J Dermatol. 1968;80(12):771–93.Google Scholar
  84. 84.
    Augey F, Renaudier P, Nicolas JF. Generalized pustular psoriasis (Zumbusch): a French epidemiological survey. Eur J Dermatol. 2006;16(6):669–73.Google Scholar
  85. 85.
    Ohkawara A, Yasuda H, Kobayashi H, Inaba Y, Ogawa H, Hashimoto I, et al. Generalized pustular psoriasis in Japan: two distinct groups formed by differences in symptoms and genetic background. Acta Derm Venereol. 1996;76(1):68–71.Google Scholar
  86. 86.
    Tay YK, Tham SN. The profile and outcome of pustular psoriasis in Singapore: a report of 28 cases. Int J Dermatol. 1997;36(4):266–71.Google Scholar
  87. 87.
    Choon SE, Lai NM, Mohammad NA, Nanu NM, Tey KE, Chew SF. Clinical profile, morbidity, and outcome of adult-onset generalized pustular psoriasis: analysis of 102 cases seen in a tertiary hospital in Johor, Malaysia. Int J Dermatol. 2014;53(6):676–84.Google Scholar
  88. 88.
    Zelickson BD, Muller SA. Generalized pustular psoriasis in childhood. Report of thirteen cases. J Am Acad Dermatol. 1991;24(2 Pt 1):186–94.Google Scholar
  89. 89.
    Borges-Costa J, Silva R, Goncalves L, Filipe P, Soares de Almeida L, Marques Gomes M. Clinical and laboratory features in acute generalized pustular psoriasis: a retrospective study of 34 patients. Am J Clin Dermatol. 2011;12(4):271–6.Google Scholar
  90. 90.
    Ritchlin CT, Kavanaugh A, Gladman DD, Mease PJ, Helliwell P, Boehncke WH, et al. Treatment recommendations for psoriatic arthritis. Ann Rheum Dis. 2009;68(9):1387–94.Google Scholar
  91. 91.
    Moll JM, Wright V. Psoriatic arthritis. Semin Arthritis Rheum. 1973;3(1):55–78.Google Scholar
  92. 92.
    Gladman DD, Antoni C, Mease P, Clegg DO, Nash P. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis. 2005;64(Suppl 2):ii14–7.PubMedPubMedCentralGoogle Scholar
  93. 93.
    Jamshidi F, Bouzari N, Seirafi H, Farnaghi F, Firooz A. The prevalence of psoriatic arthritis in psoriatic patients in Tehran, Iran. Arch Iran Med. 2008;11(2):162–5.Google Scholar
  94. 94.
    Tam LS, Tomlinson B, Chu TT, Li M, Leung YY, Kwok LW, et al. Cardiovascular risk profile of patients with psoriatic arthritis compared to controls – the role of inflammation. Rheumatology. 2008;47(5):718–23.Google Scholar
  95. 95.
    Thumboo J, Tham SN, Tay YK, Chee T, Mow B, Chia HP, et al. Patterns of psoriatic arthritis in Orientals. J Rheumatol. 1997;24(10):1949–53.Google Scholar
  96. 96.
    Yamamoto T, Yokozeki H, Nishioka K. Clinical analysis of 21 patients with psoriasis arthropathy. J Dermatol. 2005;32(2):84–90.Google Scholar
  97. 97.
    Baek HJ, Yoo CD, Shin KC, Lee YJ, Kang SW, Lee EB, et al. Spondylitis is the most common pattern of psoriatic arthritis in Korea. Rheumatol Int. 2000;19(3):89–94.Google Scholar
  98. 98.
    Deesomchok U, Tumrasvin T. Clinical comparison of patients with ankylosing spondylitis, Reiter’s syndrome and psoriatic arthritis. J Med Assoc Thail. 1993;76(2):61–70.Google Scholar
  99. 99.
    Elkayam O, Segal R, Caspi D. Human leukocyte antigen distribution in Israeli patients with psoriatic arthritis. Rheumatol Int. 2004;24(2):93–7.Google Scholar
  100. 100.
    Prasad PV, Bikku B, Kaviarasan PK, Senthilnathan A. A clinical study of psoriatic arthropathy. Indian J Dermatol Venereol Leprol. 2007;73(3):166–70.Google Scholar
  101. 101.
    Rajendran CP, Ledge SG, Rani KP, Madhavan R. Psoriatic arthritis. J Assoc Physicians India. 2003;51:1065–8.Google Scholar
  102. 102.
    Tsai YG, Chang DM, Kuo SY, Wang WM, Chen YC, Lai JH. Relationship between human lymphocyte antigen-B27 and clinical features of psoriatic arthritis. J Microbiol Immunol Infect. 2003;36(2):101–4.Google Scholar
  103. 103.
    Nossent JC, Gran JT. Epidemiological and clinical characteristics of psoriatic arthritis in northern Norway. Scand J Rheumatol. 2009;38(4):251–5.Google Scholar
  104. 104.
    Al-Awadhi AM, Hasan EA, Sharma PN, Haider MZ, Al-Saeid K. Angiotensin-converting enzyme gene polymorphism in patients with psoriatic arthritis. Rheumatol Int. 2007;27(12):1119–23.Google Scholar
  105. 105.
    Alenius GM, Jidell E, Nordmark L, Rantapaa Dahlqvist S. Disease manifestations and HLA antigens in psoriatic arthritis in northern Sweden. J Clin Rheumatol. 2002;21(5):357–62.Google Scholar
  106. 106.
    Eder L, Thavaneswaran A, Chandran V, Gladman DD. Gender difference in disease expression, radiographic damage and disability among patients with psoriatic arthritis. Ann Rheum Dis. 2013;72(4):578–82.Google Scholar
  107. 107.
    Gladman DD, Brubacher B, Buskila D, Langevitz P, Farewell VT. Psoriatic spondyloarthropathy in men and women: a clinical, radiographic, and HLA study. Clin Invest Med. 1992;15(4):371–5.Google Scholar
  108. 108.
    Queiro R, Sarasqueta C, Torre JC, Tinture T, Lopez-Lagunas I. Comparative analysis of psoriatic spondyloarthropathy between men and women. Rheumatol Int. 2001;21(2):66–8.Google Scholar
  109. 109.
    Queiro R, Tejon P, Coto P, Alonso S, Alperi M, Sarasqueta C, et al. Clinical differences between men and women with psoriatic arthritis: relevance of the analysis of genes and polymorphisms in the major histocompatibility complex region and of the age at onset of psoriasis. Clin Dev Immunol. 2013;2013:482691.PubMedPubMedCentralGoogle Scholar
  110. 110.
    Husted JA, Tom BD, Farewell VT, Schentag CT, Gladman DD. A longitudinal study of the effect of disease activity and clinical damage on physical function over the course of psoriatic arthritis: does the effect change over time? Arthritis Rheum. 2007;56(3):840–9.Google Scholar
  111. 111.
    Husted JA, Tom BD, Schentag CT, Farewell VT, Gladman DD. Occurrence and correlates of fatigue in psoriatic arthritis. Ann Rheum Dis. 2009;68(10):1553–8.Google Scholar
  112. 112.
    Queiro R, Alperi M, Lopez A, Sarasqueta C, Riestra JL, Ballina J. Clinical expression, but not disease outcome, may vary according to age at disease onset in psoriatic spondylitis. Joint Bone Spine. 2008;75(5):544–7.Google Scholar
  113. 113.
    Queiro R, Sarasqueta C, Belzunegui J, Gonzalez C, Figueroa M, Torre-Alonso JC. Psoriatic spondyloarthropathy: a comparative study between HLA-B27 positive and HLA-B27 negative disease. Semin Arthritis Rheum. 2002;31(6):413–8.Google Scholar
  114. 114.
    Ruiz DG, Azevedo MN, Lupi O. HLA-B27 frequency in a group of patients with psoriatic arthritis. An Bras Dermatol. 2012;87(6):847–50.PubMedPubMedCentralGoogle Scholar
  115. 115.
    Generali E, Scire CA, Cantarini L, Selmi C. Sex differences in the treatment of psoriatic arthritis: a systematic literature review. Isr Med Assoc J. 2016;18(3-4):203–8.Google Scholar
  116. 116.
    Lie E, van der Heijde D, Uhlig T, Heiberg MS, Koldingsnes W, Rodevand E, et al. Effectiveness and retention rates of methotrexate in psoriatic arthritis in comparison with methotrexate-treated patients with rheumatoid arthritis. Ann Rheum Dis. 2010;69(4):671–6.Google Scholar
  117. 117.
    Fabbroni M, Cantarini L, Caso F, Costa L, Pagano VA, Frediani B, et al. Drug retention rates and treatment discontinuation among anti-TNF-alpha agents in psoriatic arthritis and ankylosing spondylitis in clinical practice. Mediat Inflamm. 2014;2014:862969.Google Scholar
  118. 118.
    Glintborg B, Ostergaard M, Dreyer L, Krogh NS, Tarp U, Hansen MS, et al. Treatment response, drug survival, and predictors thereof in 764 patients with psoriatic arthritis treated with anti-tumor necrosis factor alpha therapy: results from the nationwide Danish DANBIO registry. Arthritis Rheum. 2011;63(2):382–90.Google Scholar
  119. 119.
    Glintborg B, Ostergaard M, Krogh NS, Andersen MD, Tarp U, Loft AG, et al. Clinical response, drug survival, and predictors thereof among 548 patients with psoriatic arthritis who switched tumor necrosis factor alpha inhibitor therapy: results from the Danish Nationwide DANBIO Registry. Arthritis Rheum. 2013;65(5):1213–23.Google Scholar
  120. 120.
    Heiberg MS, Koldingsnes W, Mikkelsen K, Rodevand E, Kaufmann C, Mowinckel P, et al. The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study. Arthritis Rheum. 2008;59(2):234–40.Google Scholar
  121. 121.
    Kimball AB, Gladman D, Gelfand JM, Gordon K, Horn EJ, Korman NJ, et al. National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening. J Am Acad Dermatol. 2008;58(6):1031–42.PubMedPubMedCentralGoogle Scholar
  122. 122.
    Boehncke WH, Boehncke S, Tobin AM, Kirby B. The ‘psoriatic march’: a concept of how severe psoriasis may drive cardiovascular comorbidity. Exp Dermatol. 2011;20(4):303–7.Google Scholar
  123. 123.
    Davidovici BB, Sattar N, Jörg PC, Puig L, Emery P, Barker JN, et al. Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions. J Investig Dermatol. 2010;130(7):1785–96.Google Scholar
  124. 124.
    Dreiher J, Weitzman D, Cohen AD. Psoriasis and osteoporosis: a sex-specific association. J Invest Dermatol. 2009;129(7):1643–9.Google Scholar
  125. 125.
    Bacaksiz A, Erdogan E, Sonmez O, Sevgili E, Tasal A, Onsun N, et al. Ambulatory blood pressure monitoring can unmask hypertension in patients with psoriasis vulgaris. Med Sci Monit. 2013;19:501–9.PubMedPubMedCentralGoogle Scholar
  126. 126.
    Imafuku S, Naito R, Nakayama J. Possible association of hepatitis C virus infection with late-onset psoriasis: a hospital-based observational study. J Dermatol. 2013;40(10):813–8.Google Scholar
  127. 127.
    Imafuku S, Nakayama J. Profile of patients with psoriasis associated with hepatitis C virus infection. J Dermatol. 2013;40(6):428–33.Google Scholar
  128. 128.
    Singh S, Nivash S, Mann BK. Matched case-control study to examine association of psoriasis and migratory glossitis in India. Indian J Dermatol Venereol Leprol. 2013;79(1):59.Google Scholar
  129. 129.
    Danielsen K, Wilsgaard T, Olsen AO, Eggen AE, Olsen K, Cassano PA, et al. Elevated odds of metabolic syndrome in psoriasis: a population-based study of age and sex differences. Br J Dermatol. 2015;172(2):419–27.Google Scholar
  130. 130.
    Love TJ, Qureshi AA, Karlson EW, Gelfand JM, Choi HK. Prevalence of the metabolic syndrome in psoriasis: results from the National Health and Nutrition Examination Survey, 2003-2006. Arch Dermatol. 2011;147(4):419–24.Google Scholar
  131. 131.
    Langan SM, Seminara NM, Shin DB, Troxel AB, Kimmel SE, Mehta NN, et al. Prevalence of metabolic syndrome in patients with psoriasis: a population-based study in the United Kingdom. J Invest Dermatol. 2012;132(3):556–62.Google Scholar
  132. 132.
    Mebazaa A, El Asmi M, Zidi W, Zayani Y, Cheikh Rouhou R, El Ounifi S, et al. Metabolic syndrome in Tunisian psoriatic patients: prevalence and determinants. J Eur Acad Dermatol Venereol. 2011;25(6):705–9.Google Scholar
  133. 133.
    Lakshmi S, Nath AK, Udayashankar C. Metabolic syndrome in patients with psoriasis: a comparative study. Indian Dermatol Online J. 2014;5(2):132–7.PubMedPubMedCentralGoogle Scholar
  134. 134.
    Lindegård B. Diseases associated with psoriasis in a general population of 159,200 middle-aged, urban, native Swedes. Dermatology. 1986;172(6):298–304.Google Scholar
  135. 135.
    Ghiasi M, Nouri M, Abbasi A, Hatami P, Abbasi MA, Nourijelyani K. Psoriasis and increased prevalence of hypertension and diabetes mellitus. Indian J Dermatol. 2011;56(5):533.PubMedPubMedCentralGoogle Scholar
  136. 136.
    Cohen A, Dreiher J, Shapiro Y, Vidavsky L, Vardy D, Davidovici B, et al. Psoriasis and diabetes: a population-based cross-sectional study. J Eur Acad Dermatol Venereol. 2008;22(5):585–9.Google Scholar
  137. 137.
    Murray M, Bergstresser P, Adams-Huet B, Cohen J. Relationship of psoriasis severity to obesity using same-gender siblings as controls for obesity. Clin Exp Dermatol. 2009;34(2):140–4.Google Scholar
  138. 138.
    Santos M, Fonseca HM, Jalkh AP, Gomes GP, Cavalcante Ade S. Obesity and dyslipidemia in patients with psoriasis treated at a dermatologic clinic in Manaus. An Bras Dermatol. 2013;88(6):913–6.PubMedPubMedCentralGoogle Scholar
  139. 139.
    Naito R, Imafuku S. Distinguishing features of body mass index and psoriasis in men and women in Japan: a hospital-based case-control study. J Dermatol. 2016;43:1406.Google Scholar
  140. 140.
    Finzi A, Colombo D, Caputo A, Andreassi L, Chimenti S, Vena G, et al. Psychological distress and coping strategies in patients with psoriasis: the PSYCHAE study. J Eur Acad Dermatol Venereol. 2007;21(9):1161–9.Google Scholar
  141. 141.
    Sampogna F, Tabolli S, Abeni D. Living with psoriasis: prevalence of shame, anger, worry, and problems in daily activities and social life. Acta Derm Venereol. 2012;92(3):299–303.Google Scholar
  142. 142.
    Pujol R, Puig L, Daudén E, Sánchez-Carazo J, Toribio J, Vanaclocha F, et al. Mental health self-assessment in patients with moderate to severe psoriasis: an observational, multicenter study of 1164 patients in Spain (the VACAP study). Actas Dermosifiliogr. 2013;104(10):897–903.Google Scholar
  143. 143.
    Litaiem N, Youssef S, Jabeur K, Dhaoui MR, Doss N. Affective temperament profile in psoriasis patients in Tunisia using TEMPS-A. J Affect Disord. 2013;151(1):321–4.Google Scholar
  144. 144.
    McDonough E, Ayearst R, Eder L, Chandran V, Rosen CF, Thavaneswaran A, et al. Depression and anxiety in psoriatic disease: prevalence and associated factors. J Rheumatol. 2014;41(5):887–96.Google Scholar
  145. 145.
    Wojtyna E, Lakuta P, Marcinkiewicz K, Bergler-Czop B, Brzezinska-Wcislo L. Gender, body image and social support: biopsychosocial deter-minants of depression among patients with psoriasis. Acta Derm Venereol. 2017;97:91.Google Scholar
  146. 146.
    Wu CY, Chang YT, Juan CK, Shen JL, Lin YP, Shieh JJ, et al. Depression and insomnia in patients with psoriasis and psoriatic arthritis taking tumor necrosis factor antagonists. Medicine (Baltimore). 2016;95(22):e3816.Google Scholar
  147. 147.
    Frentz G, Olsen J. Malignant tumours and psoriasis: a follow-up study. Br J Dermatol. 1999;140:237–42.Google Scholar
  148. 148.
    Lindelöf B, Sigurgeirsson B, Tegner E, Larkö O, Johannesson A, Ljunggren B, et al. PUVA and cancer risk: the Swedish follow-up study. Br J Dermatol. 1999;141:108–12.Google Scholar
  149. 149.
    Margolis D, Bilker W, Hennessy S, Vittorio C, Santanna J, Strom BL. The risk of malignancy associated with psoriasis. Arch Dermatol. 2001;137(6):778–83.Google Scholar
  150. 150.
    Brauchli YB, Jick SS, Miret M, Meier CR. Psoriasis and risk of incident cancer: an inception cohort study with a nested case–control analysis. J Invest Dermatol. 2009;129(11):2604–12.Google Scholar
  151. 151.
    Chen Y-J, Wu C-Y, Chen T-J, Shen J-L, Chu S-Y, Wang C-B, et al. The risk of cancer in patients with psoriasis: a population-based cohort study in Taiwan. J Am Acad Dermatol. 2011;65(1):84–91.Google Scholar
  152. 152.
    Lee MS, Lin RY, Chang YT, Lai MS. The risk of developing non-melanoma skin cancer, lymphoma and melanoma in patients with psoriasis in Taiwan: a 10-year, population-based cohort study. Int J Dermatol. 2012;51(12):1454–60.Google Scholar
  153. 153.
    Sterry W, Strober B, Menter A. Obesity in psoriasis: the metabolic, clinical and therapeutic implications. Report of an interdisciplinary conference and review. Br J Dermatol. 2007;157(4):649–55.Google Scholar
  154. 154.
    Dreiher J, Freud T, Cohen AD. Psoriatic arthritis and diabetes: a population-based cross-sectional study. Dermatol Res Pract. 2013;2013:580404.PubMedPubMedCentralGoogle Scholar
  155. 155.
    Gisondi P, Tessari G, Conti A, Piaserico S, Schianchi S, Peserico A, et al. Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case–control study. Br J Dermatol. 2007;157(1):68–73.PubMedPubMedCentralGoogle Scholar
  156. 156.
    Sommer DM, Jenisch S, Suchan M, Christophers E, Weichenthal M. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res. 2007;298(7):321–8.Google Scholar
  157. 157.
    Armstrong AW, Harskamp CT, Armstrong EJ. Psoriasis and metabolic syndrome: a systematic review and meta-analysis of observational studies. J Am Acad Dermatol. 2013;68(4):654–62.Google Scholar
  158. 158.
    Zindancı I, Albayrak O, Kavala M, Kocaturk E, Can B, Sudogan S, et al. Prevalence of metabolic syndrome in patients with psoriasis. Scientific World J. 2012;2012:1.Google Scholar
  159. 159.
    Meziane M, Kelati A, Najdi A, Berraho A, Nejjari C, Mernissi FZ. Metabolic syndrome in Moroccan patients with psoriasis. Int J Dermatol. 2015;55:396.Google Scholar
  160. 160.
    Nisa N, Qazi MA. Prevalence of metabolic syndrome in patients with psoriasis. Indian J Dermatol Venereol Leprol. 2010;76(6):662.Google Scholar
  161. 161.
    Kim G-W, Park H-J, Kim H-S, Kim S-H, Ko H-C, Kim B-S, et al. Analysis of cardiovascular risk factors and metabolic syndrome in Korean patients with psoriasis. Ann Dermatol. 2012;24(1):11–5.PubMedPubMedCentralGoogle Scholar
  162. 162.
    Keller JJ, Kang J-H, Lin H-C. Association between osteoporosis and psoriasis: results from the Longitudinal Health Insurance Database in Taiwan. Osteoporos Int. 2013;24(6):1835–41.PubMedPubMedCentralGoogle Scholar
  163. 163.
    Rapp SR, Feldman SR, Exum ML, Fleischer AB, Reboussin DM. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol. 1999;41(3):401–7.Google Scholar
  164. 164.
    Bhosle MJ, Kulkarni A, Feldman SR, Balkrishnan R. Quality of life in patients with psoriasis. Health Qual Life Outcomes. 2006;4(1):1.Google Scholar
  165. 165.
    Roenigk RK, Roenigk H Jr. Sex differences in the psychological effects of psoriasis. Cutis. 1978;21(4):529–33.Google Scholar
  166. 166.
    McKenna K, Stern R. The impact of psoriasis on the quality of life of patients from the 16-center PUVA follow-up cohort. J Am Acad Dermatol. 1997;36(3):388–94.Google Scholar
  167. 167.
    Gelfand JM, Feldman SR, Stern RS, Thomas J, Rolstad T, Margolis DJ. Determinants of quality of life in patients with psoriasis: a study from the US population. J Am Acad Dermatol. 2004;51(5):704–8.Google Scholar
  168. 168.
    Sampogna F, Chren M, Melchi C, Pasquini P, Tabolli S, Abeni D. Age, gender, quality of life and psychological distress in patients hospitalized with psoriasis. Br J Dermatol. 2006;154(2):325–31.Google Scholar
  169. 169.
    Grozdev I, Kast D, Cao L, Carlson D, Pujari P, Schmotzer B, et al. Physical and mental impact of psoriasis severity as measured by the compact Short Form-12 Health Survey (SF-12) quality of life tool. J Invest Dermatol. 2012;132(4):1111–6.Google Scholar
  170. 170.
    van der Velden HM, Klaassen KM, van de Kerkhof PC, Pasch MC. The impact of fingernail psoriasis on patients’ health-related and disease-specific quality of life. Dermatology. 2014;229(2):76–82.Google Scholar
  171. 171.
    Ortonne J, Baran R, Corvest M, Schmitt C, Voisard J, Taieb C. Development and validation of nail psoriasis quality of life scale (NPQ10). J Eur Acad Dermatol Venereol. 2010;24(1):22–7.Google Scholar
  172. 172.
    Augustin M, Reich K, Blome C, Schäfer I, Laass A, Radtke M. Nail psoriasis in Germany: epidemiology and burden of disease. Br J Dermatol. 2010;163(3):580–5.Google Scholar
  173. 173.
    Fernandez-Torres RM, Pita-Fernandez S, Fonseca E. Quality of life and related factors in a cohort of plaque-type psoriasis patients in La Coruna, Spain. Int J Dermatol. 2014;53(11):e507–11.Google Scholar
  174. 174.
    Rencz F, Holló P, Kárpáti S, Péntek M, Remenyik É, Szegedi A, et al. Moderate to severe psoriasis patients’ subjective future expectations regarding health-related quality of life and longevity. J Eur Acad Dermatol Venereol. 2015;29(7):1398–405.Google Scholar
  175. 175.
    Zachariae R, Zachariae H, Blomqvist K, Davidsson S, Molin L, Mørk C, et al. Quality of life in 6497 Nordic patients with psoriasis. Br J Dermatol. 2002;146(6):1006–16.Google Scholar
  176. 176.
    De Korte J, Mombers FM, Bos JD, Sprangers MA. Quality of life in patients with psoriasis: a systematic literature review. J Investig Dermatol Symp Proc. 2004;9:140.Google Scholar
  177. 177.
    Miniszewska J, Chodkiewicz J, Ograczyk A, Zalewska-Janowska A. Optimism as a predictor of health-related quality of life in psoriatics. Postepy Dermatol Alergol. 2013;30:91.PubMedPubMedCentralGoogle Scholar
  178. 178.
    Gupta MA, Gupta AK. Age and gender differences in the impact of psoriasis on quality of life. Int J Dermatol. 1995;34(10):700–3.Google Scholar
  179. 179.
    Owczarek K, Jaworski M. Quality of life and severity of skin changes in the dynamics of psoriasis. Postepy Dermatol Alergol. 2016;33(2):102–8.PubMedPubMedCentralGoogle Scholar
  180. 180.
    Schmid-Ott G, Kunsebeck H-W, Jager B, Sittig U, Hofste N, Ott R, et al. Significance of the stigmatization experience of psoriasis patients: a 1-year follow-up of the illness and its psychosocial consequences in men and women. Acta Derm Venereol. 2005;85(1):27–32.Google Scholar
  181. 181.
    Mabuchi T, Yamaoka H, Kojima T, Ikoma N, Akasaka E, Ozawa A. Psoriasis affects patient’s quality of life more seriously in female than in male in Japan. Tokai J Exp Clin Med. 2012;37(3):84–8.Google Scholar
  182. 182.
    Bohm D, Stock Gissendanner S, Bangemann K, Snitjer I, Werfel T, Weyergraf A, et al. Perceived relationships between severity of psoriasis symptoms, gender, stigmatization and quality of life. J Eur Acad Dermatol Venereol. 2013;27(2):220–6.Google Scholar
  183. 183.
    Sanchez-Carazo JL, Lopez-Estebaranz JL, Guisado C. Comorbidities and health-related quality of life in Spanish patients with moderate to severe psoriasis: a cross-sectional study (Arizona study). J Dermatol. 2014;41(8):673–8.Google Scholar
  184. 184.
    Norlin JM, Steen Carlsson K, Persson U, Schmitt-Egenolf M. Analysis of three outcome measures in moderate to severe psoriasis: a registry-based study of 2450 patients. Br J Dermatol. 2012;166(4):797–802.Google Scholar
  185. 185.
    Ayala F, Sampogna F, Romano GV, Merolla R, Guida G, Gualberti G, et al. The impact of psoriasis on work-related problems: a multicenter cross-sectional survey. J Eur Acad Dermatol Venereol. 2014;28(12):1623–32.Google Scholar
  186. 186.
    Kouris A, Christodoulou C, Stefanaki C, Livaditis M, Tsatovidou R, Kouskoukis C, et al. Quality of life and psychosocial aspects in Greek patients with psoriasis: a cross-sectional study. An Bras Dermatol. 2015;90(6):841–5.PubMedPubMedCentralGoogle Scholar
  187. 187.
    Obradors M, Blanch C, Comellas M, Figueras M, Lizan L. Health-related quality of life in patients with psoriasis: a systematic review of the European literature. Qual Life Res. 2016;25:2739.Google Scholar
  188. 188.
    Žarković Palijan T, Kovačević D, Koić E, Ružić K, Dervinja F. The impact of psoriasis on the quality of life and psychological characteristics of persons suffering from psoriasis. Coll Antropol. 2011;35(2):81–5.Google Scholar
  189. 189.
    Meeuwis K, De Hullu J, Van de Nieuwenhof H, Evers A, Massuger L, Van de Kerkhof P, et al. Quality of life and sexual health in patients with genital psoriasis. Br J Dermatol. 2011;164(6):1247–55.Google Scholar
  190. 190.
    Türel Ermertcan A, Temeltaş G, Deveci A, DinÇ G, Gueler HB, Öztürkcan S. Sexual dysfunction in patients with psoriasis. J Dermatol. 2006;33(11):772–8.Google Scholar
  191. 191.
    Hotard RS, Feldman SR, Fleischer AB. Sex-specific differences in the treatment of severe psoriasis. J Am Acad Dermatol. 2000;42(4):620–3.Google Scholar
  192. 192.
    Zachariae H, Zachariae R, Blomqvist K, Davidsson S, Molin L, Mørk C, et al. Treatment of psoriasis in the nordic countries: a questionnaire survey from 5739 members of the psoriasis associations. Acta Derm Venereol. 2001;81:116–21.Google Scholar
  193. 193.
    White D, O’Shea S, Rogers S. Do men have more severe psoriasis than women? J Eur Acad Dermatol Venereol. 2012;26(1):126–7.Google Scholar
  194. 194.
    Nyberg F, Osika I, Evengård B. “The Laundry Bag Project”–unequal distribution of dermatological healthcare resources for male and female psoriatic patients in Sweden. Int J Dermatol. 2008;47(2):144–9.Google Scholar
  195. 195.
    Waernulf L, Moberg C, Henriksson EW, Evengard B, Nyberg F. Patients’ views on care and treatment after phototherapy for psoriasis and atopic eczema including a gender perspective. J Dermatolog Treat. 2008;19(4):233–40.Google Scholar
  196. 196.
    Ormerod A, Augustin M, Baker C, Chosidow O, Cohen A, Dam T, et al. Challenges for synthesising data in a network of registries for systemic psoriasis therapies. Dermatology. 2012;224(3):236–43.Google Scholar
  197. 197.
    Gupta AK, Pandey SS, Pandey BL. Effectiveness of conventional drug therapy of plaque psoriasis in the context of consensus guidelines: a prospective observational study in 150 patients. Ann Dermatol. 2013;25(2):156–62.PubMedPubMedCentralGoogle Scholar
  198. 198.
    Al Robaee AA. The usefulness of narrowband UVB as a monotherapy for the treatment of chronic plaque psoriasis. J Drugs Dermatol. 2010;9(8):989–91.Google Scholar
  199. 199.
    Bhutani T, Wong JW, Bebo BF, Armstrong AW. Access to health care in patients with psoriasis and psoriatic arthritis: data from National Psoriasis Foundation survey panels. JAMA Dermatol. 2013;149(6):717–21.Google Scholar
  200. 200.
    Lesuis N, Befrits R, Nyberg F, van Vollenhoven RF. Gender and the treatment of immune-mediated chronic inflammatory diseases: rheumatoid arthritis, inflammatory bowel disease and psoriasis: an observational study. BMC Med. 2012;10:82.PubMedPubMedCentralGoogle Scholar
  201. 201.
    Edson-Heredia E, Sterling KL, Alatorre CI, Cuyun Carter G, Paczkowski R, Zarotsky V, et al. Heterogeneity of response to biologic treatment: perspective for psoriasis. J Invest Dermatol. 2014;134(1):18–23.Google Scholar
  202. 202.
    Salah LA, Gillstedt M, Osmancevic A. A retrospective study of patients with psoriasis treated with biologics: relation to body mass index and gender. Acta Derm Venereol. 2016;96:974.Google Scholar
  203. 203.
    Giunta A, Babino G, Manetta S, Mazzotta A, Chimenti S, Esposito M. Clinical markers predictive of primary inefficacy: a “real life” retrospective study in psoriatic patients treated with etanercept. Drug Dev Res. 2014;75(Suppl 1):S27–30.Google Scholar
  204. 204.
    Puig L, Ruiz-Salas V. Long-term efficacy, safety and drug survival of ustekinumab in a Spanish cohort of patients with moderate to severe plaque psoriasis. Dermatology. 2015;230(1):46–54.Google Scholar
  205. 205.
    De Simone C, Caldarola G, Maiorino A, Tassone F, Campana I, Sollena P, et al. Clinical predictors of nonresponse to anti-TNF-alpha agents in psoriatic patients: a retrospective study. Dermatol Ther. 2016;29:372.Google Scholar
  206. 206.
    Wu JJ, Poon KY. Association of gender, tumor necrosis factor inhibitor therapy, and myocardial infarction risk in patients with psoriasis. J Am Acad Dermatol. 2013;69(4):650–1.Google Scholar
  207. 207.
    Gniadecki R, Kragballe K, Dam T, Skov L. Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris. Br J Dermatol. 2011;164(5):1091–6.Google Scholar
  208. 208.
    Hagg D, Eriksson M, Sundstrom A, Schmitt-Egenolf M. The higher proportion of men with psoriasis treated with biologics may be explained by more severe disease in men. PLoS One. 2013;8(5):e63619.PubMedPubMedCentralGoogle Scholar
  209. 209.
    Zaghloul SS, Goodfield MJD. Objective assessment of compliance with psoriasis treatment. Arch Dermatol. 2004;140(4):408–14.Google Scholar
  210. 210.
    Uttjek M, Dufaker M, Nygren L, Stenberg B. Psoriasis care consumption and expectations from a gender perspective in a psoriasis population in northern Sweden. Acta Derm Venereol. 2005;85(6):503–8.Google Scholar
  211. 211.
    Esposito M, Gisondi P, Cassano N, Ferrucci G, Del Giglio M, Loconsole F, et al. Survival rate of antitumour necrosis factor-alpha treatments for psoriasis in routine dermatological practice: a multicentre observational study. Br J Dermatol. 2013;169(3):666–72.Google Scholar
  212. 212.
    van den Reek JM, van Lumig PP, Driessen RJ, van de Kerkhof PC, Seyger MM, Kievit W, et al. Determinants of drug survival for etanercept in a long-term daily practice cohort of patients with psoriasis. Br J Dermatol. 2014;170(2):415–24.Google Scholar
  213. 213.
    van den Reek JM, Tummers M, Zweegers J, Seyger MM, van Lumig PP, Driessen RJ, et al. Predictors of adalimumab drug survival in psoriasis differ by reason for discontinuation: long-term results from the Bio-CAPTURE registry. J Eur Acad Dermatol Venereol. 2015;29(3):560–5.Google Scholar
  214. 214.
    Gniadecki R, Bang B, Bryld L, Iversen L, Lasthein S, Skov L. Comparison of long-term drug survival and safety of biologic agents in patients with psoriasis vulgaris. Br J Dermatol. 2015;172(1):244–52.Google Scholar
  215. 215.
    Warren RB, Smith CH, Yiu ZZ, Ashcroft DM, Barker JN, Burden AD, et al. Differential drug survival of biologic therapies for the treatment of psoriasis: a prospective observational cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). J Invest Dermatol. 2015;135(11):2632–40.Google Scholar
  216. 216.
    Zweegers J, van den Reek JM, van de Kerkhof PC, Otero ME, Kuijpers AL, Koetsier MI, et al. Body mass index predicts discontinuation due to ineffectiveness and female sex predicts discontinuation due to side-effects in psoriasis patients treated with adalimumab, etanercept or ustekinumab in daily practice. A prospective, comparative, long-term drug survival study from the BioCAPTURE registry. Br J Dermatol. 2016;175:340.Google Scholar
  217. 217.
    Hetland ML, Christensen IJ, Tarp U, Dreyer L, Hansen A, Hansen IT, et al. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis Rheum. 2010;62(1):22–32.Google Scholar
  218. 218.
    Saad AA, Ashcroft DM, Watson KD, Hyrich KL, Noyce PR, Symmons DP. Persistence with anti-tumour necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics Register. Arthritis Res Ther. 2009;11(2):1.Google Scholar
  219. 219.
    Iannone F, Lopriore S, Bucci R, Scioscia C, Anelli MG, Notarnicola A, et al. Two-year survival rates of anti-TNF-alpha therapy in psoriatic arthritis (PsA) patients with either polyarticular or oligoarticular PsA. Scand J Rheumatol. 2015;44(3):192–9.Google Scholar
  220. 220.
    Generali E. Sex differences in the treatment of psoriatic arthritis: a systematic literature review. Isr Med Assoc J. 2016;18:203.Google Scholar
  221. 221.
    Amital H, Arnson Y, Chodick G, Shalev V. Hepatotoxicity rates do not differ in patients with rheumatoid arthritis and psoriasis treated with methotrexate. Rheumatology. 2009;48(9):1107–10.Google Scholar
  222. 222.
    Mancini S, Amorotti E, Vecchio S, de Leon MP, Roncucci L. Infliximab-related hepatitis: discussion of a case and review of the literature. Intern Emerg Med. 2010;5(3):193–200.Google Scholar
  223. 223.
    Mahé E, Reguiai Z, Barthelemy H, Quiles-Tsimaratos N, Chaby G, Girard C, et al. Evaluation of risk factors for body weight increment in psoriatic patients on infliximab: a multicentre, cross-sectional study. J Eur Acad Dermatol Venereol. 2014;28(2):151–9.Google Scholar
  224. 224.
    Wollina U, Hansel G, Koch A, Schönlebe J, Köstler E, Haroske G. Tumor necrosis factor-α inhibitor-induced psoriasis or psoriasiform exanthemata. Am J Clin Dermatol. 2008;9(1):1–14.Google Scholar
  225. 225.
    Ko JM, Gottlieb AB, Kerbleski JF. Induction and exacerbation of psoriasis with TNF-blockade therapy: a review and analysis of 127 cases. J Dermatol Treat. 2009;20(2):100–8.Google Scholar
  226. 226.
    Cullen G, Kroshinsky D, Cheifetz A, Korzenik J. Psoriasis associated with anti-tumour necrosis factor therapy in inflammatory bowel disease: a new series and a review of 120 cases from the literature. Aliment Pharmacol Ther. 2011;34(11–12):1318–27.Google Scholar
  227. 227.
    Shmidt E, Wetter DA, Ferguson SB, Pittelkow MR. Psoriasis and palmoplantar pustulosis associated with tumor necrosis factor-α inhibitors: the Mayo Clinic experience, 1998 to 2010. J Am Acad Dermatol. 2012;67(5):e179–e85.Google Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Sivan Sheffer Levi
    • 1
  • Yuval Ramot
    • 1
  1. 1.Department of DermatologyHadassah - Hebrew University Medical CenterJerusalemIsrael

Personalised recommendations